GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).
GRT-1C102
Phase 1 other active
Quick answer
GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial). for Ulcerative colitis is a Phase 1 program (other) at Rani Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rani Therapeutics Holdings
- Indication
- Ulcerative colitis
- Phase
- Phase 1
- Modality
- other
- Status
- active